SNOA
Sonoma Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$1.11
−2.63%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.13
From 52W high−70.79%
Volume9966.00
Market cap$5.32M
P/E (TTM)—
P/S (TTM)0.2x
Div yield—
Key dataNov 4, 2026
Open
$1.13
From 52W high
−70.79%
Volume
9966.00
Market cap
$5.32M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.5x
P/E (TTM)
—
RSI (14)
42.4
MomentumView details →
1D Return
−2.63%
YTD Return
−69.51%
SummaryUpdated Jun 1, 2026
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) is a specialty pharmaceutical company founded in 1999 and originally incorporated as Oculus Innovative Sciences before rebranding in December 2016. Based in Woodstock, Georgia, the company has developed a unique focus on stabilized hypochlorous acid (HOCl) technology for medical and healthcare applications. Since going public in 2007, Sonoma has built a portfolio of HOCl-based products spanning wound care, dermatology, eye care, oral care, and animal health markets across the United States, Latin America, Europe, and other international markets.
Similar companies
Latest newsMore news →
Sonoma Pharmaceuticals entered into a Section 382 Rights Agreement providing one preferred stock purchase right for each common share, with each right exercisable for one one-thousandth of a Series B Preferred share at $10.00, subject to adjustment.29d agoSonoma Pharmaceuticals Inc. reported its first-quarter financial results, achieving record quarterly revenue and turning EBITDA positive for the first time, with a net loss of 9 cents per share compared to a loss of 76 cents per share a year earlier.90d ago